Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

LAVAL, QC, Dec. 30, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland has granted an additional new indication for DEXAVEN...

Bausch Health's DEXAVEN (Dexamethasone Phosphate) Receives New Indication In Poland To Treat Patients With SARS-CoV-2 (COVID-19)

Bausch Health Cos. Inc. said Tuesday it is planning to pay down another $275 million of senior secured term loans, using cash on hand and cash generated from operations.

Bausch Health to repay another $275 million of senior secured term loans

No Debt Maturities or Mandatory Amortization Payments Will Be Due Until 2024 Bausch Health Will Repay Approximately $900 Million of Debt in 2020 LAVAL, QC, Dec. 29, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that on...

Bausch Health To Reduce Debt By $275 Million

Bausch Health has performed very poorly so far in 2020, but it has mostly been due to COVID-19 impacts. The pandemic has affected all of their businesses to varying degrees, but the impacts aren't permanent, and the company doesn't have much debt maturing in the near future.

Bausch Health: Wait For The Spinoff To Invest

Chiasma

Paratek Pharma

The Bruce Fund, co-managed by founder Robert Bruce (Trades, Portfolio) and his son Jeff, revealed in November that its top trades included a new position in Chiasma Inc. (NASDAQ:CHMA), position boosts in Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) and Bausch Health Companies Inc. (NYSE:BHC) and reductions in its Apple Inc. (NASDAQ:AAPL) and NextEra Energy Inc. (NYSE:NEE) holdings.

The Bruce Fund's Top 5 3rd-Quarter Trades

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Why Is Bausch (BHC) Up 13.3% Since Last Earnings Report?

Dr. Reddy's Labs

Teva Pharmaceutical

3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty

Bausch Health Companies, Inc. (BHC) Presents at Evercore ISI 3rd Annual HealthCONx Conference (Transcript)

Bausch (BHC) starts a second phase III study on its investigational treatment NOV03 for dry eye disease related to Meibomian gland dysfunction.

Bausch (BHC) Begins Second Phase III Study on NOV03 for DED

LAVAL, Quebec, Nov. 24, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") and Bausch + Lomb, its leading global eye health business, announced today that the Company has initiated the second of two Phase 3 studies evaluating the...

Bausch Health Initiates Second Phase 3 Study For NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunction

Bausch Health Companies, Inc. (BHC) Presents at Wolfe Research Healthcare Broker Conference Call - (Transcript)

Following Redemptions, Bausch Health Will Have No Note Maturities Until 2024 LAVAL, QC, Nov. 18, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has priced and upsized its previously announced offering of $1.0...

Bausch Health Announces Pricing And Upsize Of Private Offering Of Senior Notes And Conditional Redemption Of Additional Series Of Existing Senior Notes

LAVAL, QC, Nov. 18, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has launched an offering of a combined $1.75 billion aggregate principal amount of new senior notes due 2029 (the "2029 Notes") and new senior...

Bausch Health Announces Launch Of Private Offering Of Senior Notes And Conditional Redemption Of Existing Senior Notes

Let's see if Bausch Health (BHC) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Consider Bausch Health (BHC) Now?

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of capital and have to conduct due diligence while choosing their next pick. They don't always get it right, but, on average, their stock picks historically generated strong returns after adjusting for known risk factors. With this in mind, let's take a look at the recent hedge fund activity surrounding Bausch Health Companies (NYSE:BHC).

Were Hedge Funds Right About Bausch Health Companies (BHC)?

Bausch (BHC) reports better-than-expected results for the third quarter as the business shows recovery signs from the COVID-19 pandemic.

Bausch's (BHC) Q3 Earnings and Revenues Surpass Estimates

Bausch Health Companies Inc. (BHC) CEO Joe Papa on Q3 2020 Results - Earnings Call Transcript

Bausch (BHC) delivered earnings and revenue surprises of 28.43% and 1.38%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Q3 Earnings and Revenues Beat Estimates

Bausch Health Cos. Inc. shares rose 5% in premarket trade Tuesday, after the drug company's better-than-expected revenue offset weaker-than-expected profit.

Bausch Health tops revenue estimates and reiterates guidance

The former Valeant Pharmaceuticals has been completely revamped by the new executive team that was faced with a herculean task. After fighting for 4 years to deal with the massive debt load and facing massive LoE issues, the company's revenue evaporated due to Covid.

After Fighting For 4 Years, Bausch Health Is Going To Deliver

Investors are discounting the value of the B+L spinoff. Company poised to rebound as surgical procedures resume.

Why Investors Should Buy More Bausch Health Stock

Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Bausch Health (BHC)

MELBOURNE, Australia, Oct. 30, 2020 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage ophthalmology biopharmaceutical company, today announced the appointment of highly experienced ophthalmic industry expert, Tracy Valorie, as a new member to the company's Board of Directors. Ms...

PolyActiva appoints Tracy Valorie, ophthalmic industry expert and former Bausch + Lomb executive, to its Board of Directors

Eyenovia

Bausch (BHC) acquires license for an investigational microdose formulation of atropine ophthalmic solution from Eyenovia.

Bausch Acquires License for Myopia Solution from Eyenovia

The company delivered preliminary third-quarter numbers, and investors liked what they heard.

News for Bausch Health Companies Inc Stock (BHC)